The current scenario of employing loop diuretics in combination with guideline-directed medical therapy (GDMT) demonstrates a comprehensive approach to improving clinical outcomes in individuals with heart failure (HF). GDMT uses four types of drugs: angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Torsemide, furosemide, and bumetanide are common loop diuretics used to control fluid overload in HF and provide symptomatic relief. Furthermore, loop diuretics are frequently used in advanced and decompensated HF. The combination of GDMT and loop diuretics is designed to improve quality of life, reduce hospitalization rates, and increase survival. Guidelines suggest the use of low-dose loop diuretics in patients with HF who have a previous history of congestion to maintain euvolemia. According to recent studies and guidelines, individualized regimens for the use of GDMT and loop diuretics are required to optimize therapeutic efficacy in terms of clinical status, fluid retention, electrolyte balance, and renal function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.59556/japi.72.0673 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"Letter to the Editor: A Correction to [Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation]".
Clin Cardiol
January 2025
Alexandria University, Alexandria faculty of Medicine, Champollion street, Alexandria, Egypt.
We recently reviewed the article titled "Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation" published in Clinical Cardiology by [khan et al.] (1) with great interest. This study addresses a crucial area of clinical practice, and we appreciate the authors' efforts in exploring this topic.
View Article and Find Full Text PDFEfficacy of Oral Acetazolamide as Add-on Diuretic Therapy in Decongestion in Patients with Heart Failure: A Study Protocol for a Randomized Controlled Trial.
J Tehran Heart Cent
January 2024
Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Acute heart failure is a common clinical syndrome leading to hospital admission, with few evidence-based therapies for managing congestion. This trial aims to assess the efficacy of acetazolamide combined with loop diuretics in achieving decongestion among patients who fail to respond to oral diuretics and progress to acute decompensated heart failure in the absence of injectable furosemide.
Methods: This single-center, double-blind randomized controlled trial with a 1:1 allocation ratio aims to evaluate 130 patients admitted to the infusion ward.
Diuretic management protocol to improve quality and safety in managing acute heart failure in an integrated health system: An implementation science approach.
Int J Cardiol
December 2024
Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America; Department of Cardiovascular Medicine, Heart Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, United States of America; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States of America. Electronic address:
Background: Effective and timely decongestion in acute heart failure (AHF) coupled with careful discharge planning is critical in the successful treatment of patients hospitalized for AHF. We leveraged an implementation science framework to develop a health system-wide diuretic management protocol (DMP) based on emerging clinical evidence.
Methods: We conducted stakeholder interviews using the Integrated Promoting Action on Research Implementation in Health Services (iPARiHS) Framework.
Prevalence of heart failure pharmacotherapy utilisation, frailty and adverse drug events among hospitalised adults older than 75 years: a multicentre cross-sectional study.
Intern Med J
December 2024
Laboratory of Ageing and Pharmacology, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
Background: Optimal heart failure (HF) pharmacotherapy (guideline-directed medical therapy and diuretics) in older people with frailty is uncertain due to limited evidence.
Aims: To evaluate utilisation of HF pharmacotherapy and prevalence of polypharmacy, adverse drug events (ADEs), falls, delirium, renal impairment and duration of hospitalisation in older inpatients, according to frailty.
Methods: A retrospective cross-sectional study of the TO HOME cohort of 2000 inpatients ≥75 years admitted for ≥48 h to rehabilitation, geriatric or general medicine from 1 July 2016 to 30 June 2017 across six hospitals in Sydney, Australia.
Acute kidney injury and its associated factors among patients with acute decompensated heart failure admitted to the university of Gondar Hospital, Northwest Ethiopia: a hospital-based cross-sectional study.
BMC Nephrol
December 2024
Department of Internal Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Background: Heart failure often leads to hospitalization and can directly impact other organs, such as the kidneys. Acute kidney injury (AKI) is a common complication in patients hospitalized for acute decompensated heart failure (ADHF) and is associated with worse outcomes. However, there are limited data on the magnitude of AKI among hospitalized ADHF patients in resource-limited settings such as Ethiopia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!